← Eichor
Study identifier: NCT07007832 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Bile Omics for Diagnosing Indeterminate Biliary Strictures

Condition: Cholangiocarcinoma · Gallbladder Cancer and Extrahepatic Cholangiocarcinoma · Pancreatic Cancer  ·  Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

PhaseN/A
Planned participants260
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

The diagnosis of malignant biliary strictures remains a challenging aspect of biliary endoscopy. Molecular biological testing techniques based on bile have been reported to improve detection rates. However, whether the combination of bile-based omics studies and biliary brush cytology/biopsy can enhance diagnostic sensitivity has not yet been reported. This study aims to collect bile from patients with malignant biliary strictures, screen for molecular markers associated with biliary malignancies through multi-omics analysis, and subsequently validate these markers to establish a bile-based molecular diagnostic model.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaobo Cai, MD  ·  86+13918177123  ·  caixiaobo1979@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineShanghai, China, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07007832